Pharmaceutical Unit, Department of Pharmacy, Charpennes Hospital, Hospices Civils de Lyon, University Hospital of Lyon, 69100, Villeurbanne, France.
Lyon Institute for Aging, Hospices Civils de Lyon, 69000, Lyon, France.
Int J Clin Pharm. 2024 Feb;46(1):205-209. doi: 10.1007/s11096-023-01623-8. Epub 2023 Aug 2.
Patients with Alzheimer's disease and related dementias and their caregivers can be defined as people with higher risk of developing medication-related problems due to aging and polypharmacy.
To assess the medication exposure of patient with Alzheimer's disease and related dementias and their caregivers.
Ancillary cross-sectional study based on baseline medication data of the PHARMAID RCT. The PHARMAID study was a multi-center RCT assessing an integrated pharmaceutical care at a psychosocial program. Older outpatients with Alzheimer's disease and related dementias and their older caregivers were eligible for inclusion. Baseline medication data were used to assess the medication exposure, illustrated by the number of medications, the prevalence of potentially inappropriate medications (PIMs) using the EU(7)-PIM list and the Medication Regimen Complexity Index (MRCI).
Seventy-three dyads were included in this ancillary study. The mean numbers (SD) of medications used by patients was 6.8 (2.6) and by caregivers was 4.7 (3.7). Overall, 60.3% of patients used at least one PIM and 47.9% of caregivers. Regarding the medication regimen complexity, the mean MRCI was 16.3(8.1) for patients and 11.3(10.5) for caregivers.
The results of this study confirm the relevance of carrying out medication review with patients, but also with their caregivers who can be considered as hidden patients.
患有阿尔茨海默病和相关痴呆症的患者及其照护者由于年龄和多种药物治疗,可被定义为发生药物相关问题风险较高的人群。
评估阿尔茨海默病和相关痴呆症患者及其照护者的药物暴露情况。
基于 PHARMAID RCT 的基线药物数据开展辅助性横断面研究。PHARMAID 研究是一项多中心 RCT,评估了心理社会项目中整合的药物治疗管理。符合条件的参与者为患有阿尔茨海默病和相关痴呆症的老年门诊患者及其老年照护者。使用基线药物数据评估药物暴露情况,通过药物数量、使用欧盟(7)-PIM 清单的潜在不适当药物(PIM)的患病率以及药物治疗方案复杂性指数(MRCI)来表示。
这项辅助研究共纳入了 73 对患者和照护者。患者和照护者分别平均使用 6.8(2.6)和 4.7(3.7)种药物。总体而言,60.3%的患者至少使用了一种 PIM,47.9%的照护者使用了 PIM。在药物治疗方案复杂性方面,患者的平均 MRCI 为 16.3(8.1),照护者的平均 MRCI 为 11.3(10.5)。
这项研究的结果证实了对患者进行药物审查的重要性,同时也对其照护者进行药物审查,因为照护者可以被视为“隐藏患者”。